World Journal of Urology · 2021 · 12 citations · 21 references
MedicineOncologySurgeryMetastasisSurgical OncologyUrologic OncologyBladder CancerCancer StagingRadical CystectomyUrogenital Oncology SurgeryCancer Registry EvaluationLymph Node MetastasesNeoadjuvant ChemoradiationNeoadjuvant ChemoradiotherapyNeoadjuvant Radiotherapy CombinationOccult Lymph Node MetastasisSurgical DownstagingTnm Staging System
PURPOSE: Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). METHODS: Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995-December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017-October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with <(y)pT2N0 vs. <(y)pT2N+ disease was estimated by the Kaplan-Meier method. RESULTS: In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to <(y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of <(y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with <(y)pT2N+ and <(y)pT2N0, median OS was 3.5 years (95% CI 2.5-8.9) versus 12.9 years (95% CI 11.7-14.0), respectively. CONCLUSION: Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.
21
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
Nicholas D. James, Syed A. Hussain, Emma Hall et al. · New England Journal of Medicine · 2012 · 950 citations · Full text
M. K. Casparie, A.T.M.G. Tiebosch, Gary T. Burger et al. · Analytical Cellular Pathology · 2007 · 884 citations · Full text
Alan Horwich, Marek Babjuk, Joaquim Bellmunt et al. · Annals of Oncology · 2019 · 182 citations · Full text